Determination of Regulatory Review Period for Purposes of Patent Extension; Lawsonia Intracellularis Bacterin Vaccine, 16337-16338 [2017-06640]
Download as PDF
Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices
DEPARTMENT OF AGRICULTURE
Animal and Plant Health Inspection
Service
[Docket No. APHIS–2016–0115]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; Lawsonia Intracellularis
Bacterin Vaccine
Animal and Plant Health
Inspection Service, USDA.
ACTION: Notice.
AGENCY:
We are advising the public
that the Animal and Plant Health
Inspection Service has determined the
regulatory review period for Lawsonia
Intracellularis Bacterin Vaccine and is
publishing this notice of that
determination as required by law. We
have made this determination in
response to the submission of an
application to the Commissioner of
Patents and Trademarks, Department of
Commerce, for the extension of a patent
that claims that veterinary biologic.
DATES: We will consider all requests for
revision of the regulatory review period
determination that we receive on or
before May 4, 2017. We will consider all
due diligence petitions that we receive
on or before October 2, 2017.
ADDRESSES: You may submit revision
requests and due diligence petitions by
either of the following methods:
• Federal eRulemaking Portal: Go to
https://www.regulations.gov/
#!docketDetail;D=APHIS-2016-0115.
• Postal Mail/Commercial Delivery:
Please send your request or petition to
Docket No. APHIS–2016–0115,
Regulatory Analysis and Development,
PPD, APHIS, Station 3A–03.8, 4700
River Road Unit 118, Riverdale, MD
20737–1238.
A copy of the regulatory review
period determination and any revision
requests or due diligence petitions that
we receive on this determination may be
viewed at https://www.regulations.gov/
#!docketDetail;D=APHIS-2016-0115 or
in our reading room, which is located in
room 1141 of the USDA South Building,
14th Street and Independence Avenue
SW., Washington, DC. Normal reading
room hours are 8 a.m. to 4:30 p.m.,
Monday through Friday, except
holidays. To be sure someone is there to
help you, please call (202) 799–7039
before coming.
FOR FURTHER INFORMATION CONTACT: Dr.
Donna Malloy, Operational Support
Section, Center for Veterinary Biologics,
Policy, Evaluation, and Licensing, VS,
APHIS, 4700 River Road Unit 148,
Riverdale, MD 20737–1231; (301) 851–
3426.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:21 Apr 03, 2017
Jkt 241001
For information concerning the
regulatory review period determination
contact Dr. Patricia L. Foley, Center for
Veterinary Biologics, Policy, Evaluation,
and Licensing, VS, APHIS, 1920 Dayton
Avenue, P.O. Box 844, Ames, IA 50010;
(515) 337–6100.
SUPPLEMENTARY INFORMATION: The
provisions of 35 U.S.C. 156, ’’ Extension
of patent term,’’ provide, generally, that
a patent for a product may be extended
for a period of up to 5 years as long as
the patent claims a product that, among
other things, was subject to a regulatory
review period before its commercial
marketing or use. (The term ‘‘product’’
is defined in that section as ‘‘a drug
product’’ [which includes veterinary
biological products] or ‘‘any medical
device, food additive, or color additive
subject to regulation under the Federal
Food, Drug, and Cosmetic Act.’’) A
product’s regulatory review period
forms the basis for determining the
amount of extension an applicant may
receive.
The regulations in 9 CFR part 124,
‘‘Patent Term Restoration’’ (referred to
below as the regulations), set forth
procedures and requirements for the
Animal and Plant Health Inspection
Service’s (APHIS’) review of
applications for the extension of the
term of certain patents for veterinary
biological products pursuant to 35
U.S.C. 156. As identified in the
regulations, the responsibilities of
APHIS include:
• Assisting Patent and Trademark
Office of the U.S. Department of
Commerce in determining eligibility for
patent term restoration;
• Determining the length of a
product’s regulatory review period;
• If petitioned, reviewing and ruling
on due diligence challenges to APHIS’
regulatory review period
determinations; and
• Conducting hearings to review
initial APHIS findings on due diligence
challenges.
The regulations are designed to be
used in conjunction with regulations
issued by the Patent and Trademark
Office concerning patent term
extension, which may be found at 37
CFR 1.710 through 1.791.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For veterinary
biologics, the testing phase begins on
the date the authorization to prepare an
experimental veterinary biologic became
effective and runs until the approval
phase begins. The approval phase
begins on the date an application for a
license was initially submitted for
approval and ends on the date such
PO 00000
Frm 00004
Fmt 4703
Sfmt 4703
16337
license was issued. Although only a
portion of a regulatory review period
may count toward the actual amount of
extension that the Commissioner of
Patents and Trademarks may award,
APHIS’ determination of the length of a
regulatory review period for a veterinary
biologic will include all of the testing
phase and approval phase as specified
in 35 U.S.C. 156(g)(5)(B).
APHIS recently licensed for
production and marketing the veterinary
biologic Lawsonia Intracellularis
Bacterin Vaccine. Subsequent to this
approval, the Patent and Trademark
Office received a patent term restoration
application for Lawsonia Intracellularis
Bacterin Vaccine (U.S. Patent No.
5,610,059) from Intervet Inc., a
subsidiary of Merck Animal Health, and
the Patent and Trademark Office
requested APHIS’ assistance in
determining this patent’s eligibility for
patent term restoration. In a letter dated
February 19, 2016, APHIS advised the
Patent and Trademark Office that this
veterinary biologic had undergone a
regulatory review period and that the
approval of Lawsonia Intracellularis
Bacterin Vaccine represented the first
permitted commercial licensing or use
of the product. Subsequently, the Patent
and Trademark Office requested that
APHIS determine the product’s
regulatory review period.
APHIS has determined that the
applicable regulatory review period for
Lawsonia Intracellularis Bacterin
Vaccine is 1,544 days. Of this time, 186
days occurred during the testing phase
of the regulatory review period, and
1,358 days occurred during the approval
phase. These periods were derived from
the following dates:
1. The date that APHIS started
confirmatory testing on the master seed
for use in products containing Lawsonia
intracellularis: June 20, 2011. APHIS
has verified the applicant’s claim that
the master seed to be used in the
Lawsonia Intracellularis Bacterin
Vaccine was first put on test by APHIS
on June 20, 2011.
2. The date the application for a
license was initially submitted for
approval under the Virus-Serum-Toxin
Act: December 23, 2011. APHIS has
verified the applicant’s claim that the
application was initially submitted on
December 23, 2011.
3. The date the license was issued:
September 11, 2015. APHIS has verified
the applicant’s claim that the license for
the commercial marketing of the vaccine
was issued on September 11, 2015.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the Patent and Trademark
E:\FR\FM\04APN1.SGM
04APN1
16338
Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices
Office applies several statutory
limitations in its calculations of the
actual period for patent extension. In its
application for patent extension, this
applicant seeks 1,544 days of patent
term extension.
Section 124.22 of the regulations
provides that any interested person may
request a revision of the regulatory
review period determination within 30
days of the date of this notice (see DATES
above). The request must specify the
following:
• The identity of the product;
• The identity of the applicant for
patent term restoration;
• The docket number of this notice;
and
• The basis for the request for
revision, including any documentary
evidence.
Further, under § 124.30 of the
regulations, any interested person may
file a petition with APHIS, no later than
180 days after the date of this notice (see
DATES above), alleging that a license
applicant did not act with due diligence
in seeking APHIS approval of the
product during the regulatory review
period. The filing, format, and content
of a petition must be as described in the
regulations in ‘‘Subpart D–Due
Diligence Petitions’’ (§§ 124.30 through
124.33).
Authority: 35 U.S.C. 156; 7 CFR 2.22, 2.80,
and 371.4.
Done in Washington, DC, this 30th day of
March 2017.
Jere L. Dick,
Acting Administrator, Animal and Plant
Health Inspection Service.
[FR Doc. 2017–06640 Filed 4–3–17; 8:45 am]
BILLING CODE 3410–34–P
DEPARTMENT OF AGRICULTURE
Farm Service Agency
Information Collection Request;
Generic Clearance for the Collection of
Qualitative Customer Feedback on the
Farm Service Agency Service Delivery
Farm Service Agency, USDA.
Notice; request for comments.
AGENCY:
ACTION:
In accordance with the
Paperwork Reduction Act of 1995, the
Farm Service Agency (FSA) is
requesting comments from all interested
individuals and organizations on an
extension with a revision of a currently
approved information collection
associated with the Generic Clearance
for the Collection of Qualitative
Customer Feedback on FSA Service
Delivery. This option is a fast track for
approval to streamline the timing to
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:21 Apr 03, 2017
Jkt 241001
implement certain types of surveys and
related collection of information. FSA
uses the approval to cover the
instruments of collection (such as a
survey, a window pop-up survey, a
focus group, or a comment card), which
are designed to get customer feedback
on FSA service delivery for various
programs. This request for approval
broadly addresses FSA’s need for
information about what our customers
think of our services so that we can
improve service delivery; specific
information collection activities will be
incorporated into the approval as the
need for the information is identified.
For example, when we implement a
new program and provide information
about the services for the program on
our Web site, we may provide a
voluntary customer service
questionnaire about how well the
program is working for our customers,
specifically within the area of customer
service. FSA is requesting to increase
the number of respondents in the fast
track approval due to an anticipated
increase in the number of customer
respondents responding to customer
service surveys that will be sent to a
broader scope and greater number of
FSA customers.
DATES: We will consider comments that
we receive by June 5, 2017.
ADDRESSES: We invite you to submit
comments on this notice. In your
comments, include the date, volume,
and page number of this issue of the
Federal Register, the OMB control
number and the title of the information
collection. You may submit comments
by any of the following methods:
• Federal eRulemaking Portal: Go to
https://www.regulations.gov. Follow the
online instructions for submitting
comments.
• Mail: Mary Ann Ball, USDA, Farm
Service Agency, Room 3754–S, 1400
Independence Ave SW., Washington,
DC 20250–0572.
You may also send comments to the
Desk Officer for Agriculture, Office of
Information and Regulatory Affairs,
Office of Management and Budget,
Washington, DC 20503.
Copies of the information collection
instruments may be requested by
contacting Mary Ann Ball at the above
address.
FOR FURTHER INFORMATION CONTACT:
Mary Ann Ball, (202) 720–4283.
SUPPLEMENTARY INFORMATION:
Title: Generic Clearance for the
Collection of Qualitative Customer
Feedback on Farm Service Agency
Service Delivery.
OMB Control Number: 0560–0286.
PO 00000
Frm 00005
Fmt 4703
Sfmt 4703
Type of Request: Extension with a
revision.
Abstract: FSA program staff have
created several feedback instruments
(customer surveys) and submitted them
to the FSA information collection
coordinator for approval under the
current approved information collection
of 0560–0286, Generic Clearance for the
Collection of Qualitative Customer
Feedback on Farm Service Agency
Service Delivery. FSA program staff
continue to use the fast track approval
to submit a new customer instruments
to the FSA information collection
coordinator for approval, which takes
less time rather than going through a
regular Paperwork Reduction Act
process. As a result, program staff are
able to quickly implement certain types
of surveys and related collection of
information using OMB control number
of 0560–0286. For example, when we
implement a new program and provide
information about the programs on our
Web site, FSA may provide a voluntary
customer service questionnaire about
how well the program is working for our
customers, specifically within the area
of customer service. The information
collection provides a means to gather
qualitative customer and stakeholder
feedback in an efficient, timely manner
that is consistent with FSA’s
commitment to improving service
delivery. By qualitative feedback, we
mean information, generally from
customers, that provides useful insights
on perceptions and opinions based on
experiences with FSA service delivery.
Such information does not include
statistical surveys that yield quantitative
results that can be generalized to the
population. The qualitative feedback
will:
• Provide insights into customer or
stakeholder perceptions, experiences,
and expectations,
• Provide an early warning of issues
with service, and
• Focus attention on areas where
communication, training, or changes in
operations might improve delivery of
products or services.
The collection will allow for ongoing,
collaborative, and actionable
communication between FSA and its
customers and stakeholders. It will also
allow feedback to contribute directly to
the improvement of program
management.
The solicitation of feedback will target
areas such as: Timeliness,
appropriateness, accuracy of
information, courtesy, efficiency of
service delivery, and resolution of
issues with service delivery. Responses
will be assessed to plan and inform
efforts to improve or maintain the
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 82, Number 63 (Tuesday, April 4, 2017)]
[Notices]
[Pages 16337-16338]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-06640]
[[Page 16337]]
-----------------------------------------------------------------------
DEPARTMENT OF AGRICULTURE
Animal and Plant Health Inspection Service
[Docket No. APHIS-2016-0115]
Determination of Regulatory Review Period for Purposes of Patent
Extension; Lawsonia Intracellularis Bacterin Vaccine
AGENCY: Animal and Plant Health Inspection Service, USDA.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: We are advising the public that the Animal and Plant Health
Inspection Service has determined the regulatory review period for
Lawsonia Intracellularis Bacterin Vaccine and is publishing this notice
of that determination as required by law. We have made this
determination in response to the submission of an application to the
Commissioner of Patents and Trademarks, Department of Commerce, for the
extension of a patent that claims that veterinary biologic.
DATES: We will consider all requests for revision of the regulatory
review period determination that we receive on or before May 4, 2017.
We will consider all due diligence petitions that we receive on or
before October 2, 2017.
ADDRESSES: You may submit revision requests and due diligence petitions
by either of the following methods:
Federal eRulemaking Portal: Go to https://www.regulations.gov/#!docketDetail;D=APHIS-2016-0115.
Postal Mail/Commercial Delivery: Please send your request
or petition to Docket No. APHIS-2016-0115, Regulatory Analysis and
Development, PPD, APHIS, Station 3A-03.8, 4700 River Road Unit 118,
Riverdale, MD 20737-1238.
A copy of the regulatory review period determination and any
revision requests or due diligence petitions that we receive on this
determination may be viewed at https://www.regulations.gov/#!docketDetail;D=APHIS-2016-0115 or in our reading room, which is
located in room 1141 of the USDA South Building, 14th Street and
Independence Avenue SW., Washington, DC. Normal reading room hours are
8 a.m. to 4:30 p.m., Monday through Friday, except holidays. To be sure
someone is there to help you, please call (202) 799-7039 before coming.
FOR FURTHER INFORMATION CONTACT: Dr. Donna Malloy, Operational Support
Section, Center for Veterinary Biologics, Policy, Evaluation, and
Licensing, VS, APHIS, 4700 River Road Unit 148, Riverdale, MD 20737-
1231; (301) 851-3426.
For information concerning the regulatory review period
determination contact Dr. Patricia L. Foley, Center for Veterinary
Biologics, Policy, Evaluation, and Licensing, VS, APHIS, 1920 Dayton
Avenue, P.O. Box 844, Ames, IA 50010; (515) 337-6100.
SUPPLEMENTARY INFORMATION: The provisions of 35 U.S.C. 156, ''
Extension of patent term,'' provide, generally, that a patent for a
product may be extended for a period of up to 5 years as long as the
patent claims a product that, among other things, was subject to a
regulatory review period before its commercial marketing or use. (The
term ``product'' is defined in that section as ``a drug product''
[which includes veterinary biological products] or ``any medical
device, food additive, or color additive subject to regulation under
the Federal Food, Drug, and Cosmetic Act.'') A product's regulatory
review period forms the basis for determining the amount of extension
an applicant may receive.
The regulations in 9 CFR part 124, ``Patent Term Restoration''
(referred to below as the regulations), set forth procedures and
requirements for the Animal and Plant Health Inspection Service's
(APHIS') review of applications for the extension of the term of
certain patents for veterinary biological products pursuant to 35
U.S.C. 156. As identified in the regulations, the responsibilities of
APHIS include:
Assisting Patent and Trademark Office of the U.S.
Department of Commerce in determining eligibility for patent term
restoration;
Determining the length of a product's regulatory review
period;
If petitioned, reviewing and ruling on due diligence
challenges to APHIS' regulatory review period determinations; and
Conducting hearings to review initial APHIS findings on
due diligence challenges.
The regulations are designed to be used in conjunction with
regulations issued by the Patent and Trademark Office concerning patent
term extension, which may be found at 37 CFR 1.710 through 1.791.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For veterinary biologics, the
testing phase begins on the date the authorization to prepare an
experimental veterinary biologic became effective and runs until the
approval phase begins. The approval phase begins on the date an
application for a license was initially submitted for approval and ends
on the date such license was issued. Although only a portion of a
regulatory review period may count toward the actual amount of
extension that the Commissioner of Patents and Trademarks may award,
APHIS' determination of the length of a regulatory review period for a
veterinary biologic will include all of the testing phase and approval
phase as specified in 35 U.S.C. 156(g)(5)(B).
APHIS recently licensed for production and marketing the veterinary
biologic Lawsonia Intracellularis Bacterin Vaccine. Subsequent to this
approval, the Patent and Trademark Office received a patent term
restoration application for Lawsonia Intracellularis Bacterin Vaccine
(U.S. Patent No. 5,610,059) from Intervet Inc., a subsidiary of Merck
Animal Health, and the Patent and Trademark Office requested APHIS'
assistance in determining this patent's eligibility for patent term
restoration. In a letter dated February 19, 2016, APHIS advised the
Patent and Trademark Office that this veterinary biologic had undergone
a regulatory review period and that the approval of Lawsonia
Intracellularis Bacterin Vaccine represented the first permitted
commercial licensing or use of the product. Subsequently, the Patent
and Trademark Office requested that APHIS determine the product's
regulatory review period.
APHIS has determined that the applicable regulatory review period
for Lawsonia Intracellularis Bacterin Vaccine is 1,544 days. Of this
time, 186 days occurred during the testing phase of the regulatory
review period, and 1,358 days occurred during the approval phase. These
periods were derived from the following dates:
1. The date that APHIS started confirmatory testing on the master
seed for use in products containing Lawsonia intracellularis: June 20,
2011. APHIS has verified the applicant's claim that the master seed to
be used in the Lawsonia Intracellularis Bacterin Vaccine was first put
on test by APHIS on June 20, 2011.
2. The date the application for a license was initially submitted
for approval under the Virus-Serum-Toxin Act: December 23, 2011. APHIS
has verified the applicant's claim that the application was initially
submitted on December 23, 2011.
3. The date the license was issued: September 11, 2015. APHIS has
verified the applicant's claim that the license for the commercial
marketing of the vaccine was issued on September 11, 2015.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the Patent and
Trademark
[[Page 16338]]
Office applies several statutory limitations in its calculations of the
actual period for patent extension. In its application for patent
extension, this applicant seeks 1,544 days of patent term extension.
Section 124.22 of the regulations provides that any interested
person may request a revision of the regulatory review period
determination within 30 days of the date of this notice (see DATES
above). The request must specify the following:
The identity of the product;
The identity of the applicant for patent term restoration;
The docket number of this notice; and
The basis for the request for revision, including any
documentary evidence.
Further, under Sec. 124.30 of the regulations, any interested
person may file a petition with APHIS, no later than 180 days after the
date of this notice (see DATES above), alleging that a license
applicant did not act with due diligence in seeking APHIS approval of
the product during the regulatory review period. The filing, format,
and content of a petition must be as described in the regulations in
``Subpart D-Due Diligence Petitions'' (Sec. Sec. 124.30 through
124.33).
Authority: 35 U.S.C. 156; 7 CFR 2.22, 2.80, and 371.4.
Done in Washington, DC, this 30th day of March 2017.
Jere L. Dick,
Acting Administrator, Animal and Plant Health Inspection Service.
[FR Doc. 2017-06640 Filed 4-3-17; 8:45 am]
BILLING CODE 3410-34-P